<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05051956</url>
  </required_header>
  <id_info>
    <org_study_id>Geriatric-CDK4/6</org_study_id>
    <nct_id>NCT05051956</nct_id>
  </id_info>
  <brief_title>Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?</brief_title>
  <official_title>Evaluation of the G8 Questionnaire and the Groningen Frailty Indicator to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Namik Kemal University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Namik Kemal University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CDK 4/6 inhibitors (palbociclib, ribociclib) have taken their place in our practice recently&#xD;
      with their clinical benefits in the treatment of hormone-positive and HER2 negative&#xD;
      metastatic breast cancer. Abemaciclib, another CDK 4/6 inhibitor, is not frequently preferred&#xD;
      because of reimbursement problems in Turkey. The most obvious advantages of CDK 4/6&#xD;
      inhibitors are that they are used orally and have relatively fewer side effects against&#xD;
      chemotherapy. Neutropenia, diarrhea, elevation in liver function tests are the main&#xD;
      dose-limiting side effects. In the geriatric age group, it can be thought that the expected&#xD;
      benefit from the treatment will not be achieved in cases where these side effects cannot be&#xD;
      predicted or managed well. The geriatric age group (65 years and older) deserves special&#xD;
      attention in oncology practice, considering both the treatments and the disease itself.&#xD;
      Although a number of very useful clinical scales have been developed regarding this subject,&#xD;
      it is important that the scale used should be comprehensive as well as being easily&#xD;
      applicable for integrating it into daily practice. Geriatric 8 (G8) was found to be a highly&#xD;
      sensitive test based on a comprehensive geriatric examination, while the Groningen frailty&#xD;
      scale with high specificity. The common feature of these two tests is that they are suitable&#xD;
      for daily practice as they are easy to fill. In the light of this information, we aimed to&#xD;
      examine whether the G8 and Groningen frailty scale could shed light on clinicians in&#xD;
      predicting side effects during the use of CDK 4/6 inhibitors (palbociclib and ribociclib) in&#xD;
      geriatric breast cancer patients. We also aimed to reveal the adverse events of these CDK 4/6&#xD;
      inhibitors as real-life experience.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>6 months period</time_frame>
    <description>First and second adverse events</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors</condition>
  <arm_group>
    <arm_group_label>CDK4/6 inhibitors</arm_group_label>
    <description>The patient who is started on one of the CDK 4/6 inhibitors (palbociclib 125 mg 3 weeks on 1 week off) or ribociclib 600 mg 3 weeks on 1 week off) will be followed up for adverse events.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib 125mg and Ribociclib 600 mg</intervention_name>
    <description>Administration of Palbociclib or Ribociclib</description>
    <arm_group_label>CDK4/6 inhibitors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Geriatric (65 years and older) breast cancer patients treated with CDK4/6 inhibitors&#xD;
        (Palbociclib or Ribociclib)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Breast cancer 65 years and older Treated with CDK 4/6 inhibitors (Palbociclib or&#xD;
             Ribociclib)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Below 65 years old&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birol Ocak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uludag University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Özlem Aydın İsak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara Dışkapı Yıldırım Beyazıd Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elif Şenocak Taşçı, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mehmet Ali Aydınlar Acıbadem University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seher Yıldız Tacar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Sadi Konuk Bakırköy Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Müslih Ürün, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eskişehir City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sema Türker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zonguldak Atatürk Public Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Turgut Kaçan, Assoc. Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bursa Yüksek İhtisas Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Özlem Özdemir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>İzmir Bozyaka Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eda Tanrıkulu Şimşek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haydarpaşa Numune Training and Research Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hasan Çağrı Yıldırım, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hacettepe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teoman Şakalar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kahramanmaraş Necip Fazıl City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gülhan İpek Deniz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Private Tansan Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mustafa Ersoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eskişehir Osmangazi University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yusuf Karakaş, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Acıbadem Bodrum Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ezgi Değerli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>İstanbul University Cerrahpaşa Medicine Faculty</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hacer Demir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Afyon University of Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sinem Akbaş, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Koç University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmet Gülmez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>İnönü University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Özkan Alan, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tekirdağ Fehmi Cumalıoğlu City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rukiye Arıkan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Marmara University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Özden Özer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dokuz Eylul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sercan Ön, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zahid Koçak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necmettin Erbakan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nil Molinas Mandel, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Koç University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Onur Eşbah, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Düzce University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ali İnal, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mersin City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murat Araz, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Necmettin Erbakan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Halil Taşkaynatan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>İzmir Private Ege City Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdullah Sakin, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Van Yüzüncü Yıl University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eyyüp Çavdar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tekirdağ Namık Kemal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kubilay Karaboyun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tekirdağ Namık Kemal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erdoğan Selçuk Şeber, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tekirdağ Namık Kemal University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Okan AVCI, MD</last_name>
    <phone>05302073000</phone>
    <email>drokanavci@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yakup İriağaç, MD</last_name>
    <phone>+905321579248</phone>
    <email>yakupiriagac@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tekirdağ Namık Kemal University</name>
      <address>
        <city>Tekirdağ</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Okan AVCI, MD</last_name>
      <email>drokanavci@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Namik Kemal University</investigator_affiliation>
    <investigator_full_name>Asoc. Prof. Erdoğan Selçuk Şeber</investigator_full_name>
    <investigator_title>Assoc. Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

